Citius Oncology (CTOR) Accumulated Expenses (2023 - 2026)

Citius Oncology's Accumulated Expenses history runs 4 years deep, the most recent figure standing at $24.1 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 175.82% year-over-year to $24.1 million; the TTM figure through Mar 2026 stood at $24.1 million (up 175.82% YoY), while the FY2025 annual figure was $4.1 million, changed N/A from the prior year.
• Accumulated Expenses was $24.1 million for Q1 2026 at Citius Oncology, up from $4.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $24.1 million in Q1 2026 to a low of $5001.0 in Q4 2023.
• Historically, Accumulated Expenses has averaged $5.2 million across 4 years, with a median of $4.1 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses soared 124447.33% in 2024, then slumped 34.78% in 2025.
• A 4-year view of Accumulated Expenses shows it stood at $5001.0 in 2023, then jumped by 124447.33% to $6.2 million in 2024, then plunged by 34.78% to $4.1 million in 2025, then surged by 492.19% to $24.1 million in 2026.
• The last three Accumulated Expenses figures came in at $24.1 million (Q1 2026), $4.1 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.